:

What is the miracle arthritis drug for dogs?

Humberto Batz
Humberto Batz
2025-08-24 06:49:01
Count answers : 22
0
Your dog may have been prescribed a drug called Librela, which is a convenient monthly injection for dogs. The active ingredient is a monoclonal antibody (bedinvetmab) which specifically targets a protein called Nerve Growth Factor (NGF). This inhibits NGF function and in doing so, provides relief from pain associated with osteoarthritis. Most patients will respond to the first injection though some will take two doses before significant benefit is seen. Side effects are extremely rare, and it is safe to use with most other medications. It is only licenced for use in dogs over 12 months old but not in pregnant or lactating bitches, or in those intended for breeding.
Maynard O'Conner
Maynard O'Conner
2025-08-15 00:35:51
Count answers : 23
0
The FDA approved Librela, a monoclonal antibody drug used for the control of pain associated with osteoarthritis in dogs, on May 5, 2023, and it was introduced to the marketplace later that year. Librela is dosed by weight and labeled for subcutaneous injection once a month. Prior to approval, the FDA reviewed available studies and other data on Librela and determined Librela to be safe and effective for its intended use for control of pain associated with osteoarthritis in dogs. The FDA monitors the safety profile of all animal drugs after they reach the market, as widespread use of a drug in a large number of patients may uncover adverse events not observed prior to approval. The FDA’s Center for Veterinary Medicine (CVM) is committed to promoting and protecting animal health by ensuring marketed animal drugs are safe and effective.
Dedric Kozey
Dedric Kozey
2025-08-05 19:34:44
Count answers : 23
0
Librela is the first monoclonal antibody the FDA has approved for use in dogs. The FDA approved Librela for the control of pain associated with osteoarthritis in dogs. Librela can help control the pain associated with the condition. Bedinvetmab, the active ingredient in Librela, works by binding to and inhibiting the biological activity of a protein called canine nerve growth factor, which has been found to be elevated in dogs with OA and is involved in the regulation of pain. When bedinvetmab binds to NGF, it prevents the pain signal from reaching the brain. The weight of evidence from the two field studies demonstrated that Librela is effective at controlling pain associated with OA in dogs when at least two doses are given 28 days apart. OA is the most common form of arthritis in dogs, it is estimated that it affects at least 25 percent of dogs at some point in their lifetime. Librela is given by subcutaneous injection once a month and dosed by weight range to target a minimum dose of 0.5 mg/kg.